Lucía Núñez

Dr. Lucía Núñez

Departamento de Ciencias de la Salud, Grupo de Investigación Cardiovascular (GRINCAR), Universidade da Coruña, Coruña, Spain
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2006 in Cardiovascular Research
Verified
Journal Article
Closed access
Lucía NúñezLucía Núñez
Lucía Núñez
MVM Vaquero
M Vaquero
RGR Gomez
R Gomez
RCRicardo Caballero
Ricardo Caballero
PMP Mateoscaceres
P Mateoscaceres
JTJ Tamargo
J Tamargo
This study was undertaken to analyze whether nitric oxide (NO) modulates the human potassium channel hKv1.5, which generates the ultrarapid delayed rectifier current (IKur) that determines the height and duration of atrial action potentials. Currents were recorded using the whole-cell patch-clamp in Ltk- cells expressing hKv1.5 channels. The NO donors (+/-)-S-Nitroso-N-acetylpenicillamine (SNAP) and sodium nitroprusside, a NO solution, and l-Arginine inhibited hKv1.5 currents in a concentration-dependent manner. The NO concentration in the cell chamber was monitored using a sensor, and the IC50 for NO-induced hKv1.5 block was 340+/-70 nM. SNAP also inhibited the IKur recorded in mouse ventricular myocytes. The NO effects were partially mediated by the activation of the soluble guanylate cyclase (sGC)/cGMP/cGMP-dependent protein kinase (PKG) pathway. The biotin-switch assay demonstrated the presence of S-nitrosylated cysteines (Cys) on the hKv1.5 protein in SNAP-treated cells. Molecular modeling of hKv1.5 channel structure suggests that S-nitrosylation of Cys331 (segment 2, S2) and Cys346 (S2) would be stabilized by hydrogen bridge bonds with Ile262 (S1) and Arg342 (S2), respectively. NO inhibits the hKv1.5 current by a cGMP-dependent mechanism and by the S-nitrosylation of the hKv1.5 protein, an effect that contributes to shaping the human atrial action potentials.

18 November 2010 in Heart
Verified
Journal Article
Closed access
PDF file
MOM José Oliva-Sandoval
M José Oliva-Sandoval
FRFrancisco Ruiz-Espejo
Francisco Ruiz-Espejo
LMLorenzo Monserrat
Lorenzo Monserrat
MHManuel Hermida-Prieto
Manuel Hermida-Prieto
MMMaria Sabater Molina
Maria Sabater Molina
MVMariano Valdés
Mariano Valdés
Background Mutations in the cardiac myosin-binding protein C (MYBPC3) gene are frequently found as a cause of hypertrophic cardiomyopathy (HCM). However, only a few studies have analysed genotype–phenotype correlations in small series of patients. The present study sought to determine the clinical characteristics, penetrance and prognosis of HCM with an identical mutation in MYBPC3. Methods 154 non-related patients with HCM (aged 55±16 years, 100 (64.9%) males) were studied. 18 (11.7%) were found to have an identical mutation in the MYBPC3 gene (IVS23+1G→A). Pedigree analysis, including both clinical evaluation and genotyping, was performed. Results 152 individuals (mean age 37±18 years, 53.3% males) from 18 families were evaluated. 65 carriers of the IVS23+1G→A mutation were identified, 61.5% of whom met HCM diagnostic criteria. Penetrance of the disease increased with age, with 50% affected at 46 years of age. Males tended to develop the disease earlier than females. 7 (15.6%) had systolic dysfunction. Compared with the rest of the HCM cohort, probands with the mutation had more hypertrophy and were younger at diagnosis. There was a trend towards a reduced survival free from sudden death (SD) (HR 1.71; 95% CI 0.98 to 2.98, p=0.059). There were 17 SD cases in 12 families with the mutation. Conclusions The MYBPC3 IVS23+1G→A mutation is associated with middle-age onset disease and poor outcome, with a significant proportion of patients developing systolic impairment and a high SD risk profile.

4 August 2008 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
RGRicardo Gómez
Ricardo Gómez
Lucía NúñezLucía Núñez
Lucía Núñez
MVMiguel Vaquero
Miguel Vaquero
IAIrene Amorós
Irene Amorós
ABAdriana Barana
Adriana Barana
EDEva Delpón
Eva Delpón
Chronic atrial fibrillation (CAF) is characterized by a shortening of the plateau phase of the action potentials (AP) and a decrease in the bioavailability of nitric oxide (NO). In this study, we analysed the effects of NO on Kv4.3 (IKv4.3) and on human transient outward K+ (Ito1) currents as well as the signalling pathways responsible for them. We also analysed the expression of NO synthase 3 (NOS3) in patients with CAF. IKv4.3 and Ito1 currents were recorded in Chinese hamster ovary cells and in human atrial and mouse ventricular dissociated myocytes using the whole-cell patch clamp. The expression of NOS3 was analysed by western blotting. AP were recorded using conventional microelectrode techniques in mouse atrial preparations. NO and NO donors inhibited IKv4.3 and human Ito1 in a concentration- and voltage-dependent manner (IC50 for NO: 375.0 ± 48 nM) as a consequence of the activation of adenylate cyclase and the subsequent activation of the cAMP-dependent protein kinase and the serine–threonine phosphatase 2A. The density of the Ito1 recorded in ventricular myocytes from wild-type (WT) and NOS3-deficient mice (NOS3−/−) was not significantly different. Furthermore, the duration of atrial AP repolarization in WT and NOS3−/− mice was not different. The increase in NO levels to 200 nM prolonged the plateau phase of the mouse atrial AP and lengthened the AP duration measured at 20 and 50% of repolarization of the human atrial CAF-remodelled AP as determined using a mathematical model. However, the expression of NOS3 was not modified in left atrial appendages from CAF patients. Our results suggested that the increase in the atrial NO bioavailability could partially restore the duration of the plateau phase of CAF-remodelled AP by inhibiting the Ito1 as a result of the activation of non-canonical enzymatic pathways.

1 February 2013 in Heart Rhythm
Verified
Journal Article
Closed access
Lucía NúñezLucía Núñez
Lucía Núñez
ABAdriana Barana
Adriana Barana
IAIrene Amorós
Irene Amorós
MFMarta González de la Fuente
Marta González de la Fuente
PDPablo Dolz-Gaitón
Pablo Dolz-Gaitón
JTJuan Tamargo
Juan Tamargo

1 April 2007 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JTJuan Tamargo
Juan Tamargo
RCRicardo Caballero
Ricardo Caballero
RGRicardo Gómez
Ricardo Gómez
Lucía NúñezLucía Núñez
Lucía Núñez
MVMiguel Vaquero
Miguel Vaquero
EDEva Delpón
Eva Delpón

1 April 2004 in Cardiovascular Research
Verified
Journal Article
Closed access
RCRicardo Caballero
Ricardo Caballero
RGRicardo Gómez
Ricardo Gómez
IMIgnacio Moreno
Ignacio Moreno
Lucía NúñezLucía Núñez
Lucía Núñez
TGTeresa González
Teresa González
EDEva Delpón
Eva Delpón
The Ca2+ -independent transient outward K+ current (Ito) plays a crucial role in shaping the cardiac action potential. In the present study, we examined whether angiotensin II (AngII) regulated the Ito as well as the putative intracellular cascade responsible for the effects. Ito was recorded in rat ventricular myocytes using the nystatin-perforated patch-clamp configuration. AngII (0.1 microM) inhibited Ito (21.9+/-4.8% at +40 mV), but not the IK1, in a voltage- and time-independent manner. The inhibition decreased at concentrations higher than 1 microM resulting in a bell-shaped dose-response curve (IC50 = 3.1+/-1.5 microM). The blocking effects were abolished in the presence of the type 2 AngII receptor (AT2R) antagonist PD123319, but not in the presence of the selective type 1 AngII receptor (AT1R) antagonist candesartan. Moreover, the selective AT2R agonist CGP42112A completely reproduced the effects of AngII (20.5+/-2.4% of block at +40 mV), indicating that AngII-induced Ito block was mediated via stimulation of AT2R. Furthermore, selective stimulation of AT2R by CGP42112A significantly prolonged the rat atrial action potentials recorded using conventional microelectrode techniques. The AngII-induced inhibition of I(to) was not modified by either Npi-nitro-L-arginine-methyl ester (L-NAME) or eicosatetrayonic acid (ETYA), indicating that neither the nitric oxide (NO)-guanosine 3',5'-cyclic monophosphate (cGMP) system nor the arachidonic acid cascade was implicated in the effects of AngII on Ito. However, the AngII-induced Ito inhibition was completely abolished by the serine/threonine phosphatase type 2A (PP2A) inhibitors, okadaic acid and cantharidin, but not by the inactive analog of okadaic acid, 1-norokadaone. Intracellular application of PP2A decreased Kv4.2 currents recorded in transiently transfected Chinese hamster ovary cells (CHO). These results indicate that AngII activates PP2A through the stimulation of the AT2R, resulting in a decrease of the Ito amplitude.